Fatigue in immune thrombocytopenia by Hill, QA & Newland, AC
Fatigue in immune thrombocytopenia
Quentin A. Hill1 and Adrian C. Newland2
1Department of Haematology, St James’s University Hospital, Leeds, and 2Department of Haematology, The Royal London Hospital,
London, UK
Summary
Fatigue is an important aspect of health-related quality of life
from the patient perspective and can have significant socio-
economic consequences. It is a common feature of chronic
illnesses and a significant number of both adults and children
with immune thrombocytopenia (ITP) suffer from fatigue.
Reliable, validated fatigue scales have been developed for use
in ITP. These will facilitate future investigation of its patho-
genesis and the effectiveness of intervention. Acute inflam-
mation acts on neural and endocrine systems resulting in
‘sickness behaviour’, an adaptive response to infection and
injury. Inflammation is also thought to cause fatigue in
chronic disease and immune dysregulation in ITP appears to
have a number of pro-inflammatory components. Clinicians
should consider fatigue when assessing the burden of disease.
Although effective ITP-directed therapy can improve fatigue,
a number of fatigue-directed strategies may also need to be
considered.
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Immune thrombocytopenia (ITP) is an acquired immune-
mediated disorder associated with a reduced platelet count
and may present with bruising and bleeding. Primary (idio-
pathic) ITP is rare, with an incidence of approximately 4–6
per 100 000 per year (Gernsheimer, 2008; Schoonen et al,
2009). Bleeding risk rises as the platelet count falls and for
patients with a platelet count <30 9 109/l, risk of fatal haem-
orrhage (usually intracranial) has been estimated at 0016–
0039 cases per patient-year, although factors such as age also
affect risk (Cohen et al, 2000). However, many have only
minor mucosal bleeding or a tendency to bruise easily, one
quarter are asymptomatic at presentation and those with
mild disease do not usually require treatment. ITP is not
purely a bleeding disorder and, paradoxically, an increased
rate of venous thrombosis has been observed (Severinsen
et al, 2011). Patient-reported outcomes help quantify the
impact of a disease and its treatments on well being, daily
life and physical, psychological and social functioning (Math-
ias et al, 2008). These are typically assessed with a health-
related quality of life (HRQoL) questionnaire and HRQoL
has been shown to be significantly reduced in patients with
ITP compared to controls (McMillan et al, 2008; Snyder
et al, 2008). In one study, HRQoL was similar to patients
with diabetes mellitus and worse than those with other
chronic diseases including hypertension, arthritis and cancer
(McMillan et al, 2008).
Fatigue is one of the most common and distressing symp-
toms for patients with a chronic disease. It is a frequent
symptom of autoimmune disorders and affects 80–93% of
patients with rheumatoid arthritis (Huyser et al, 1998), 50–
92% with systemic lupus erythematosis (SLE) (Schmeding &
Schneider, 2013) and 68% with primary biliary cirrhosis
(Cauch-Dudek et al, 1998). The negative impact of fatigue
on task completion makes it an important public health
issue, and in the United States, workers with fatigue cost
employers $1364 billion annually in lost productive time
(Ricci et al, 2007). Patients with ITP also complain of fatigue
and many feel that they have less energy when the platelet
count is low (Cines & Bussel, 2005; Newton et al, 2011). We
aim to review the evidence that ITP results in fatigue, the
reasons why fatigue could develop and future prospects for
research and clinical practice.
How do you define and measure fatigue?
Historically, studies of physical illness have rarely addressed
fatigue, possibly because it is a subjective complaint that is
difficult to define and measure. This lack of a clear and
widely accepted definition is illustrated by cancer-related fati-
gue, for which 24 different definitions have been put forward
by experts (Barsevick et al, 2010). Fatigue would be typically
defined as: extreme and persistent tiredness, weakness or
exhaustion – mental, physical or both (Dittner et al, 2004).
This is usually experienced in the absence of any excessive
expenditure of energy as a cause and is often associated with
decreased functioning, e.g. difficulty completing tasks.
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In clinical studies, fatigue is usually measured using a
self-assessment fatigue scale or questionnaire. This may be
uni-dimensional (e.g. the Fatigue Severity Scale), multi-dimen-
sional (e.g. the Visual Analogue Scale for Fatigue) or form part
of a broader index of outcome [e.g. the Medical Outcomes
Study Short Form-36 (SF-36)]. Fatigue scales [reviewed in
detail elsewhere (Dittner et al, 2004)] should be reliable, vali-
dated and applicable to the patient population being studied.
Several disease-specific HRQoL tools that include evaluation
of fatigue have been developed for, or validated in ITP
patients. For example, the ITP Patient Assessment Question-
naire (ITP-PAQ) has demonstrated acceptable reliability and
validity (Mathias et al, 2007) and has chiefly been used in clin-
ical trials of romiplostim. In the ITP-PAQ, patients are asked
how often in the last 4 weeks did ITP or its treatments cause
them to be physically fatigued, on a 5-point scale from ‘all the
time’ to ‘never’. In trials of eltrombopag, fatigue was primarily
assessed using the fatigue subscale of the Functional Assess-
ment of Chronic Illness Therapy (FACIT-F) questionnaire. FA-
CIT-F was originally designed for use in cancer but has been
validated in other chronic diseases and its reliability and valid-
ity was also demonstrated in ITP patients, along with the SF-
36v2 (Signorovitch et al, 2011). The FACIT-F consists of 13
questions related to fatigue, rated on a scale of 0 ‘not at all’ to
4 ‘very much’.
Do patients with ITP suffer from fatigue?
In a series of focus groups, 14/23 ITP patients identified fati-
gue as an important issue (Mathias et al, 2008). In a qualita-
tive postal survey of patients with primary ITP, 790 patients
(696 adults, 94 children) returned a complete survey (45%
response rate) (Sarpatwari et al, 2010a) and 125% ‘always’
or ‘often’ missed work or school due to fatigue. A further
survey assessed 585 UK and 93 US patients with primary ITP
using the Fatigue Impact Scale (FIS) (Newton et al, 2011).
The FIS is a multidimensional assessment of the impact of
fatigue on cognitive, physical and psychosocial function that
has been validated in a number of chronic disease states. Sig-
nificant fatigue (FIS ≥ 40) was found in 39% (UK) and 22%
(US) of patients, significantly more than the 25% expected
in normal subjects. A smaller study reported a history of fati-
gue in 22% (6/27) of children with ITP (Blatt et al, 2010). In
two controlled trials of romiplostim in ITP (n = 125), the
baseline assessment of HRQoL by ITP-PAQ found that of 44
items evaluated, fatigue was among the five worst scores
(George et al, 2009). In the RAISE study of elthrombopag
(n = 197), the mean baseline FACIT-F score was lower in
ITP patients than the general US population, suggesting a
greater burden of fatigue (Signorovitch et al, 2011). Taken
together, these studies provide evidence that fatigue occurs in
a significant proportion of patients with ITP.
It is less clear whether fatigue is associated with disease
severity as measured by the platelet count. In one question-
naire, school or work absence due to fatigue did not signifi-
cantly correlate to the platelet count (<20, 20–49 or
>50 9 109/l) at last follow-up (Sarpatwari et al, 2010a) and
in an assessment of 236 adult ITP patients with the Chinese
(mainland) version of the SF-36, the platelet count (<30, 30–
100 > 100 9 109/l) was not a significant predictor of energy/
vitality (Zhou et al, 2007). In contrast, the study of Newton
et al (2011) found that 69% of patients in the UK cohort
and 50% of patients in the US cohort reported that they had
less energy when their platelet count was low. Further analy-
sis revealed that a platelet count <100 9 109/l in patients
with bleeding symptoms, and a platelet count <30 9 109/l in
patients without bleeding, were independent risk factors for
fatigue. Additionally, in a 52 week study of romiplostim ver-
sus standard of care, overall treatment responders (platelet
count ≥ 50 9 109/l) had significantly less fatigue (Kuter
et al, 2012).
Why do patients with ITP become fatigued?
The causes of ITP-associated fatigue are not fully understood.
However, there is sufficient understanding of the pathogene-
sis of fatigue in other chronic diseases to form hypotheses
for testing (Fig 1). In some patients, ITP is secondary to a
condition such as SLE that is itself associated with fatigue.
There may be an associated disorder, such as hypothyroid-
ism, or existing co-morbidities and in one ITP study, the
presence of other medical problems was an independent pre-
dictor of fatigue (Newton et al, 2011). Thrombocytopenia
can affect other aspects of HRQoL that may indirectly influ-
ence mood and energy levels. For example, in one question-
naire, 23% of children and 95% of adults were frustrated by
activity restrictions and there was a negative impact on social
engagement (Sarpatwari et al, 2010a). Sleep and mood dis-
turbance are often associated with fatigue in chronic disease
(Nikolaus et al, 2013; Schmeding & Schneider, 2013) and
daytime sleepiness has been independently associated with
ITP-associated fatigue (Newton et al, 2011). Pre-morbid psy-
chological symptoms and lack of exercise predict develop-
ment of chronic fatigue syndrome (CFS) and post-infectious
fatigue (Lewis & Wessely, 1992) while early life stress is a risk
factor for both inflammation and fatigue in later life (Bower,
2012). Social and behavioural predictors of fatigue in chronic
disease include lack of social support (Nikolaus et al, 2013;
Schmeding & Schneider, 2013), negative interpersonal events
(Nikolaus et al, 2013), low self-efficacy expectations towards
coping (Riemsma et al, 1998) or other negative illness beliefs
(Joyce et al, 1997). Some factors, such as mood, illness belief,
social support and ability to work, may be both cause and
consequence of fatigue and have a dynamic bi-directional
interaction with fatigue (Hewlett et al, 2011).
The impact of medical therapy
Medical therapy may influence fatigue, either negatively
through toxicity, or positively through disease control. As the
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need for therapy is likely to be a surrogate for disease activ-
ity, it will be difficult to untangle their relative contribution
to fatigue without longitudinal studies. There is little data on
the impact of splenectomy on fatigue. In one study, sub-
group analysis of a standard of care arm found that HRQoL
including fatigue was not significantly different before and
after splenectomy but the analysis lacked statistical power
(n = 13) (Kuter et al, 2012).
Corticosteroids and immunosuppressive therapy
Corticosteroids have multiple side effects that could contrib-
ute to fatigue, including sleep disturbance, a range of psychi-
atric reactions, fluid retention, acne, muscle weakness,
proximal myopathy and susceptibility to infection. In a study
of 986 adult ITP patients, 25/33 steroid-related symptoms,
including fatigue, occurred more frequently in current corti-
costeroid users than patients who had not received steroids
(Berti et al, 2008). Fatigue was one of the most frequent and
distressing symptoms in both groups. In a further study, fati-
gue was associated with steroid treatment in univariate but
not multivariate analysis (Newton et al, 2011).
The side effects of immunosuppressive therapy, such as
infection and anaemia, may also lead to fatigue, although the
mechanisms of drug induced fatigue are not fully understood
(Zlott & Byrne, 2010). Thiopurines, such as azathioprine,
have been recognized to cause fatigue in patients with
inflammatory bowel disease (Lee et al, 2009). In patients
with primary refractory ITP receiving ciclosporin, fatigue was
reported as a side effect in 2/12 (Emilia et al, 2002) and 2/10
(Kappers-Klunne & van’t Veer, 2001) cases. In a randomized
control trial (RCT) of first line rituximab versus rituximab
and dexamethasone for primary ITP, fatigue was the most
frequently reported adverse event (c. 40%) and was not
significantly more common with the addition of steroids
(Gudbrandsdottir et al, 2013). Interestingly, in a placebo-
controlled RCT of patients with primary ITP, 22% (7/32)
complained of fatigue after receiving rituximab compared
with 8% (2/26) receiving placebo, although the difference
was not tested for significance (Arnold et al, 2012).
Thrombopoietin receptor agents
Thrombopoietin receptor agonists (thrombomimetics) stimu-
late platelet production and are a relatively targeted therapy.
In trials of romiplosim and eltrombopag, fatigue was not
reported as an adverse event more frequently than in patients
receiving placebo (Cuker, 2010). Thrombomimetics are effec-
tive with response rates of approximately 80% (Provan et al,
2010). If fatigue is associated with disease severity, effective
targeted treatment might be expected to improve fatigue.
However despite a reduction in bleeding events and an over-
all improvement in HRQoL with romiplostim (Kuter et al,
2010; Stasi et al, 2012) and eltrombopag (Cheng et al, 2011;
Tarantino et al, 2013), neither treatment was able to show a
consistent and clinically significant improvement in fatigue.
There was no difference in fatigue between eltrombopag and
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Fig 1. Model of the pathogenesis of ITP-associated fatigue. ITP, immune thrombocytopenia; B cell, autoantibody producing B lymphocytes; T
cell Th1, T lymphocytes with a T helper 1 polarization; TNF-a, tumour necrosis factor alpha; IFN-c, interferon gamma; MP, microparticles;
CNS, central nervous system. *T cells can attack platelets directly, secrete pro-inflammatory cytokines and drive formation of autoreactive B cells.
This results in antibody- and complement-mediated platelet destruction. Platelet microparticles are prothrombotic and able to activate the proin-
flammatory complement pathway.
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although a significant improvement in vitality (physical or
mental fatigue) in the SF-36v2 was found in the eltrombopag
arm compared with baseline and placebo (Cheng et al,
2011). When romiplostim was assessed in two phase III trials
of splenectomized and non-splenectomized patients after
24 weeks, the ITP-PAQ showed no improvement in fatigue
from baseline in patients receiving treatment or placebo
(George et al, 2009). When non-splenectomized patients
were assessed at 52 weeks in an open-label study, the ITP-
PAQ fatigue score was significantly improved from baseline
after treatment with both standard of care and romiplostim
arms. However the change in fatigue for both arms did not
meet criteria for a clinically significant improvement. A clini-
cally significant improvement was identified in treatment
responders versus treatment non-responders and the failure
to demonstrate this with romiplostim may therefore reflect
dilution of the treatment effect by non-responders (Kuter
et al, 2012). Alternatively, if ITP-related fatigue is partly dri-
ven by immune dysregulation and cytokine pathways, its
pathophysiology may not be affected by a targeted thromb-
omimetic.
Bruising and bleeding
Bruising and bleeding can lead to anaemia and iron defi-
ciency although information is limited on their prevalence in
ITP patients. Iron deficiency in pre-menopausal women can
cause fatigue, even in the absence of anaemia (Wang et al,
2013) and this fatigue is correctable with iron replacement
therapy (Krayenbuehl et al, 2011). Anaemia may be exacer-
bated by medical therapy or arise from an underlying cause
of ITP. For example, anaemia is found in approximately 50%
of patients with SLE (Giannouli et al, 2006). An additional
consequence of bruising is highlighted by a survey in which
135% of women had attempted to conceal bruises and 7%
felt people suspected bruising had resulted from physical vio-
lence (Sarpatwari et al, 2010a). Visible bruising can therefore
cause social embarrassment and this was identified by ITP
patient focus groups as a limitation on social and leisure
activities leading to a reduced HRQoL (Mathias et al, 2008).
Furthermore, as previously noted, negative social interaction
can lead to fatigue. In a postal survey, bruising and bleeding
symptoms were significantly associated with fatigue in uni-
variate but not multivariate analysis (Newton et al, 2011).
Disease activity
Immune thrombocytopenia is a disorder of immune dysregu-
lation. In other chronic disorders, fatigue appears to be dri-
ven by immune activation and pro-inflammatory processes.
Although this association awaits investigation in ITP, recent
developments in the understanding of its pathophysiology
suggest a role for pro-inflammatory cytokines. Cytokines,
such as interleukin (IL) 1b (IL1B), IL6 and tumour necrosis
factor (TNF) a are normally produced in response to infec-
tion or tissue injury. Cytokines can then enter the central
nervous system (CNS) through leaky regions of the blood
brain barrier, be carried across by transporters, relay cytokine
signals by activation of peripheral nerve afferents or recruit
activated immune cells which then enter the CNS (Felger &
Miller, 2012). This leads to neuroinflammation by stimulat-
ing local inflammatory signalling pathways (e.g. nuclear fac-
tor kappa B, mitogen-activated protein kinases) and further
cytokine production in astrocytes and microglial cells. This
in turn alters neurotransmitter metabolism and affects endo-
crine pathways, for example stimulating corticotrophin
releasing hormone (Miller et al, 2008) and suppressing thy-
rotropin releasing hormone (Kamath et al, 2009). These cen-
tral effects promote fever and result in lethargy, anhedonia
(loss of ability to experience pleasure), decreased libido, sleep
disturbance and anorexia (Adelman & Martin, 2009). This
‘sickness behaviour’ favours survival by directing energy
towards healing and can be reproduced by infusion of IL1 in
animals (Dunn, 2006). However, when inflammation persists
in chronic disease, these effects are no longer adaptive (Felger
& Miller, 2012). The concept of inflammatory sickness
behaviour helps explain why the overlapping co-morbidities
of depression, sleep disturbance and fatigue are so often seen
together in patients with cancer (Miller et al, 2008) and
chronic disease (Swain, 2000; Nikolaus et al, 2013; Schme-
ding & Schneider, 2013). Inflammatory cytokines are raised
in depression (Anderson et al, 2014) and CFS (Brenu et al,
2011). They are also associated with fatigue in patients with
cancer (Schubert et al, 2007) and diabetes mellitus (Lasselin
et al, 2012). In human studies, treatment with interferon
(IFN) or IL6 often induces fatigue (Spath-Schwalbe et al,
1998) while inhibition of IL6 or TNFa can reduce it (Monk
et al, 2006; Rohleder et al, 2012).
A pro-inflammatory environment in ITP is supported by
the observation that thromboembolic events (TE’s) can occur
in patients despite thrombocytopenia and, in one study, 21%
(9/43) of TE’s occurred when the platelet count was
<50 9 109/l (Ruggeri et al, 2014). ITP patients who develop
thrombosis have been found to have a significantly lower
presenting platelet count than those who did not (Ruggeri
et al, 2014), suggesting thrombosis may be a marker of dis-
ease severity. Another study noted a non-significant trend
towards a lower presenting platelet count in those who devel-
oped TE’s (Sarpatwari et al, 2010b). Platelets play an impor-
tant role in thrombosis, inflammation and vascular injury.
Proposed mechanisms of thrombosis in ITP include a greater
proportion of young activated platelets and greater release of
platelet microparticles (Aledort et al, 2004; Ruggeri et al,
2014). Activated platelets and platelet microparticles have an
intrinsic capacity to activate the alternative and classical
complement pathways on/near their surface, with measurable
increases in soluble inflammatory mediators C3a and C5a
(Peerschke et al, 2010). This immune-mediated complement
activation is found in ITP patients, in whom greater activa-
tion is associated with a lower platelet count (Peerschke et al,
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2010). Additionally, microparticle-associated procoagulant
activity has been shown to be higher in ITP patients than
healthy controls (Alvarez Roman et al, 2014). These observa-
tions also support a pro-inflammatory and pro-thrombotic
environment in patients with ITP.
The pathogenesis of ITP and the cytokine milieu
The pathogenesis of ITP is likely to be complex and may
vary between patients. As well as antibody production by
auto-reactive B lymphocytes against platelets and megakaryo-
cytes, there can be platelet lysis by CD8+ cytotoxic lympho-
cytes (Olsson et al, 2003). Although some self-reactive T cells
survive as part of the normal immune repertoire, self toler-
ance mechanisms include control by T regulatory cells
(Tregs), while auto-reactive B cells are progressively removed
during maturation in the bone marrow (Cooper & Bussel,
2006). In ITP, most studies have found a reduction in circu-
lating Tregs (Semple & Provan, 2012). There is also evidence
of an abnormal cytokine environment. A CD4+ T helper cell
type 1 (Th1) cell response is characterized by increased IL2,
while Th2 cells produce ILs 4, 5, 6, 9, 10 and 13. In patients
with ITP, cytokine profiles in plasma and peripheral blood
mononuclear cells demonstrate a greater Th1/Th2 profile
(Semple et al, 1996; Panitsas et al, 2004; Wang et al, 2005).
A Th1 profile is supported by the finding of an increase in
the pro-inflammatory IL18, which promotes a Th1 response.
In addition, there is a decrease in the anti-inflammatory
transforming growth factor beta-1 (TGFb-1; TGFB1) which
would otherwise promote the formation of Tregs and inhibit
lymphocyte proliferation and differentiation into Th1 or Th2
phenotypes (Zhao et al, 2014).
Further evidence for the significance of inflammatory
cytokines in ITP pathogenesis comes from studies showing
that certain genetic polymorphisms associated with cytokine
production are more likely in ITP patients. For example, car-
riers of the IL1RN*2 allele were more common in 122 ITP
patients compared with 541 blood donors and this allele was
associated with higher IL1 [a (IL1A) and b (IL1B)] levels in
both groups (Rocha et al, 2010). Gene polymorphisms linked
to production of IL2, IL4, IL10, TNFa (TNF), TNFb (LTA)
and the anti-inflammatory IL1 receptor antagonist have also
been associated with individuals developing ITP (Rocha et al,
2010; Pesmatzoglou et al, 2012). This is particularly interest-
ing because variant alleles of pro-inflammatory cytokine
genes have been associated with a greater risk of fatigue in
cancer patients undergoing various therapies (Bower, 2012).
Some studies have found different plasma cytokine profiles
in ITP patients (Del Vecchio et al, 2012; Culic et al, 2013) and
there are a number of potentially confounding variables. The
increase in plasma cytokines, such as IL1B following immune
challenge is often transient (Wood & Weymann, 2013) and the
ability to detect them can deteriorate with suboptimal sample
processing, temperature and duration of storage (Schubert
et al, 2007). An individual’s cytokine profile can be further
influenced by: age (Ma et al, 2008), genetic polymorphisms in
genes involved in the pro-inflammatory immune response
(Rocha et al, 2010), use of therapeutic agents such as steroids
(Zhan et al, 2014), time of day (Schubert et al, 2007), sleep
disruption (Schubert et al, 2007) and disease activity (Panitsas
et al, 2004). Absolute individual cytokine levels may be physio-
logically less important than relative concentrations of antago-
nizing cytokines (Panitsas et al, 2004) and the method of
analysing multiple cytokines may need to evolve to understand
this, e.g. as components of Th1, Th2 and Th17 responses. For
example, in patients with CFS the use of a cytokine co-expres-
sion network analysis revealed an established Th2 inflamma-
tory milieu and attenuated Th1 and Th17 immune responses
(Broderick et al, 2010).
As well as a direct effect of pro-inflammatory cytokines on
neurotransmitters, such as serotonin (Anderson et al, 2014; If-
uku et al, 2014) and dopamine (Felger & Miller, 2012; Bower
& Lamkin, 2013), IFNc (IFNG) and IL6 may also act indirectly
by inducing expression of indoleamine 2,3-dioxygenase (IDO).
IDO increases breakdown of the serotonin precursor trypto-
phan via the kynurenine pathway. Several downstream path-
way metabolites, such as quinolinic acid and kyurenic acid,
also have neuroregulatory activity. Inflammatory IDO induc-
tion appears to have an antimicrobial function but it also
increases immune tolerance by inducing formation of Tregs
and limiting T-cell proliferation (Kwidzinski & Bechmann,
2007). The Th1 cytokine profile seen in ITP patients would be
expected to induce IDO and yet, as seen in other autoimmune
disorders, there is reduced IDO expression in dendritic cells
(Wang et al, 2011; Xu et al, 2012) resulting in reduced Tregs
and impaired self tolerance (Catani et al, 2013). The mecha-
nism is unclear and one study found no evidence of impaired
IFNc receptor expression to explain the failure of dendritic
cells to up-regulate IDO (Catani et al, 2013). A further study
found reduced IDO expression in CD4+ and CD8+ T-cells but
increased in CD19+ and CD14+ cells (Wang et al, 2011). These
findings suggest that IDO expression within immune effector
cells has an important role in the pathogenesis of ITP.
Although not studied in ITP, inflammatory cytokines within
the CNS increase IDO expression thereby influencing neuro-
peptides (Felger & Miller, 2012) and this may be a step in the
pathogenesis of fatigue.
Future prospects
A significant proportion of ITP patients suffer from fatigue,
but the symptom is less common than in other chronic dis-
eases. With a heterogeneous pathogenesis, ITP therefore pre-
sents an opportunity to better understand which aspects of
immune dysregulation might lead to fatigue. Studies need to
be well powered and longitudinal if they are to determine
causality between variables with probable association, such as
mood disorder and sleep disturbance. Longitudinal assess-
ment with validated fatigue scales, such as FACIT-F and ITP-
PAQ, can also be used to assess the effectiveness of interven-
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tions. It would be illuminating to map fatigue symptoms
against markers of immune function, such as T and B lym-
phocyte activity and inflammatory cytokines. The platelet
count has limitations as a surrogate marker of ITP disease
activity and inflammatory biomarkers could be tested for
their association with bleeding score and other aspects of
HRQoL as well as fatigue. Potential candidates for further
study would include microparticle procoagulant activity,
inflammatory gene polymorphisms and cytokines such as
IL1b, IL6, IL18, IFNc, TGFb1 and neopterin (produced by
IFNc-stimulated monocytes). However extended cytokine
analysis may be necessary to fully characterize the profile of
an individual’s immune dysregulation. Due to the dynamic
nature of cytokines, multiple daily blood samples and daily
fatigue assessments would be ideal (Schubert et al, 2007),
with control and documentation of sampling and storage
conditions. A limitation of studying plasma is that cytokine
levels may not reflect activity in immune effector cells or the
CNS. For investigation of the central pathogenesis of fatigue,
promising non-invasive imaging techniques include proton
magnetic resonance spectroscopic imaging to assess in-vivo
brain metabolites (Gabbay et al, 2010) and positron emission
tomography (Capuron et al, 2007), however animal models
may also be useful in understanding CNS pathways.
In clinical practice, a validated screening tool to identify
patients with clinically significant fatigue is needed. Screening
could usefully cover other components of HRQoL, such as
sleep, mood, family or financial pressures and such general
tools exist, for example, The Distress Thermometer Screening
Tool, which has been validated for cancer patients (Jacobsen
et al, 2005). Meanwhile, fatigue should be actively sought, with
moderate or severe symptoms prompting more detailed
enquiry. Thus far, effective ITP therapy is the best-studied
route to improving fatigue but understanding its pathogenesis
may present other targets for intervention. For example,
potentially treatable factors should be identified, such as sleep
disturbance, anaemia or iron deficiency, mood disorder or
psychosocial issues, co-morbid disorders and medication side
effects. These may require medication but non-pharmacologi-
cal interventions have been effective in patients with other
causes of chronic fatigue. In CFS, illness belief is an important
predictor of outcome (Joyce et al, 1997) and interventions
such as education, cognitive behavioural therapy (CBT) and
exercise have GRADE 1A evidence for their effectiveness. The
importance of stress reduction and sleep are also emphasized
with a focus on self management strategies (Clauw, 2014). In
patients with cancer-associated fatigue, yoga and CBT were
both shown to reduce inflammatory markers and fatigue
symptoms (Bower & Lamkin, 2013). Other non-pharmacolog-
ical approaches to cancer-associated fatigue include physical
activity, complementary therapies (e.g. relaxation, massage,
acupuncture), energy conservation (finding a balanced routine
of activity and rest), sleep therapies (e.g. sleep hygiene through
comfortable sleep surroundings and avoiding caffeine or exer-
cise before sleep) and psychosocial therapies (counselling,
spiritual care and distraction, e.g. reading, walking or garden-
ing) (Koornstra et al, 2014).
Although no fatigue-directed pharmacological therapy is
yet in use, there are a number of potential candidates. In a
meta-analysis of 8 randomized controlled trials of adjunctive
melatonin 20 mg once daily during chemotherapy or radio-
therapy for solid organ cancer, it was shown to significantly
reduce fatigue (P < 000001) (Wang et al, 2012). In patients
with CFS, a cross-over study (n = 63) found agomelatine, a
melatonin receptor agonist and serotonin-2C receptor antag-
onist that increases pre-frontal dopaminergic and noradren-
ergic tone, significantly reduced fatigue (Pardini et al, 2014).
A small randomized placebo-controlled study found a signifi-
cant reduction in cancer-associated fatigue and sleep distur-
bance in patients receiving thyrotropin releasing hormone
(Kamath et al, 2009). Dopaminergic therapies, such as meth-
ylphenidate, amantadine and modafinil, have also been used
to combat fatigue but with mixed results (Peuckmann et al,
2010; Sheng et al, 2013).
Conclusion
Fatigue is an important morbidity from the patient perspec-
tive. The presence of fatigue has been established in a signifi-
cant proportion of patients with ITP. The development of
validated, reproducible, disease-specific tools for accessing
HRQoL and fatigue has now paved the way for further
enquiry into its pathogenesis. Studies of fatigue in chronic
disease have found an association between fatigue and symp-
toms, such as mood and sleep disturbance, and these may be
linked through inflammatory processes. The reasons for fati-
gue are likely to be multiple, vary between individuals and
vary for an individual during the course of their illness and
treatment. Longitudinal studies are needed to explore the
factors contributing to ITP-related fatigue.
Clinicians should assess fatigue symptoms and other
aspects of HRQoL alongside lifestyle, bleeding symptoms and
the platelet count when considering when to intervene with
ITP-directed therapy. The effectiveness of non-pharmacologi-
cal interventions for fatigue have not been studied in ITP
patients but are effective in other chronic disorders, have few
adverse effects and may be underutilized.
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